Aehr Test Systems (AEHR) - Stock Analysis

Last updated: Apr 4, 2026

TechnologyClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

High-risk semiconductor test beneficiary with an imminent catalyst: multiple recent production orders (FOX wafer-level systems, silicon-photonics and GaN programs), reinstated H2 revenue guidance ($25–30M) and a sharp rebound (~+31% from March 30 to April 1) into the 2026-04-07 Q3 earnings release create a classic near-term event/momentum setup.

Loading chart data...

Idea window: 4/2/2026 – 4/9/2026Sector: Technology

AI Analyst Overview

Last Price
$68.86
Market Cap
$2.17B
1D Return
+9.02%
YTD Return
+241.06%

Loading chart data...

Valuation Metrics

P/E
-185.2
P/B
15.2
P/S
47.9
EV/EBITDA
-159.7
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Strong liquidity • Compressed margins • High working‑capital Aehr shows strong liquidity and low leverage but deteriorating margins, rising operating losses, and heavy working-capital drag that challenge profitability and valuation.

Liquidity
Margins

Price Behavior

7.0

Key Price Behavior Insights: • Clear breakout • Rapid rally • Pullback risk Support Level: $37.0–$38.5; stronger support $30.12 Resistance Level: $44.3 AEHR has broken out last month into a clear short-term uptrend (closing $44.32) well above the ~$37.7 average, showing strong momentum but a rapid ~47% rise from $30.12 that raises near-term pullback risk.

momentum
overbought

Sentiment & News

7.0

Key News Insights: • AI/data-center wins • Sharp share rally • Weak fundamentals Aehr Test Systems is seeing investor-driven rallies on AI/data-center silicon-photonics wins and a major customer order despite weak recent revenue and profitability, mixed analyst views, and stretched valuation ahead of fiscal Q3 results.

AI
Valuation
AI

AI Summary

6.0
Neutral

Aehr's transition from an R&D vendor to an early commercial supplier with production‑level AI and silicon‑photonics wins meaningfully raises upside if a few large programs scale into repeatable, higher‑margin production — but the investment now hinges on execution timing and customer concentration. Investors should make exposure conditional: validate by Q3 revenue/margin delivery, multi‑quarter repeat bookings beyond single orders, and rapid inventory conversion before increasing positions; a miss likely triggers sharp downside given the current valuation and momentum.

ProductionUpside
ConcentrationRisk
CatalystDriven
AI summary updated 5 days ago

Description

Aehr Test Systems designs and supplies test and burn-in equipment for logic, memory and optical integrated circuits, supporting both wafer-level and packaged-device verification. Its product set includes systems and handling solutions that enable full-wafer contact testing, singulated die and module burn-in, and compact single-wafer reliability checks across a range of device types and power levels. The company was incorporated in 1977 and is based in Fremont, California.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Apr 2Apr 9AEHRAehr Test Systems
High-risk semiconductor test beneficiary with an imminent catalyst: multiple recent production orders (FOX wafer-level systems, silicon-photonics and GaN programs), reinstated H2 revenue guidance ($25–30M) and a sharp rebound (~+31% from March 30 to April 1) into the 2026-04-07 Q3 earnings release create a classic near-term event/momentum setup.
Closed+55.4%
Mar 9Mar 16AEHRAehr Test Systems
Semicap name with stacked recent orders: in Feb–early Mar 2026 announced multiple production-stage and wafer-level burn-in orders (including a $14M FOX + WaferPak order on 2026-02-26 and a follow-on silicon-photonics order on 2026-03-03). Stock ran ~55% into a 44.03 high then pulled back ~19% to 35.61 by 2026-03-06, leaving a high-volatility setup where confirmation of order-to-revenue conversion could trigger another sharp upside leg.
Closed-8.3%
Feb 23Mar 2AEHRAehr Test Systems
An initial production purchase order from a leading hyperscaler for multiple Sonoma systems and more than $5.5m in recent Q3 orders, tied to next‑gen AI processors, is catalyzing strong technical momentum (break around $34) and elevated investor interest, positioning AEHR for near‑term upside as those orders convert to reported revenue despite weak recent cash flow and margins.
Closed+28.3%
Dec 17Dec 24AEHRAehr Test Systems
Record Q3 revenues with strong AI/data center product demand, production capacity expansion, institutional buying, and improving gross margins underpin short-term growth, although unprofitability and technical price volatility suggest cautious optimism.
Closed+2.7%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.